Benazepril Dosage Calculator for Dogs (ACE-Inhibitor)

Benazepril for Dogs – ACE-Inhibitor for Heart + Kidneys

Benazepril is an angiotensin-converting enzyme inhibitor (ACE-i) used in dogs for congestive heart failure (CHF), chronic kidney disease with proteinuria, systemic hypertension, and protein-losing nephropathy.

Standard Dose

0.25-0.5 mg/kg PO every 24 hours

For protein-losing nephropathy: 0.5-1.0 mg/kg q12-24h (higher dose)

Dose Reference Table

Tablet sizes: 2.5, 5, 10, 20, 40 mg (uncoated splittable).

Brand names: Fortekor (veterinary), Lotensin (human), generic widely available.

Why Benazepril vs Enalapril?

Indications + Evidence

Standard CHF Quad Therapy

CKD Proteinuria Protocol (IRIS)

1. UPC 0.2-0.5 – monitor; lifestyle/diet changes
2. UPC over 0.5 – START benazepril 0.25 mg/kg q24h
3. Inadequate response 4-8 weeks – increase to 0.5 mg/kg OR add telmisartan
4. Target: 50% UPC reduction or normalization
5. Monitor renal values + K+ closely
6. Renal diet essential adjunct

⚠ Triple Whammy Warning

ACE-i + Diuretic + NSAID = Acute Kidney Injury risk

Common scenario: older dog with CHF + arthritis. AVOID NSAIDs in dogs on benazepril + furosemide.

Use instead:

• Gabapentin 10-20 mg/kg q8-12h
• Librela (bedinvetmab) anti-NGF monthly injection
• Adequan injections
• Omega-3
• Acupuncture
• Physical therapy
• Weight management

Monitoring Schedule

• Baseline: BUN, creatinine, Na, K, Cl, UPC ratio, BP
• 5-7 days after starting or dose change – watch for acute decompensation
• 2-4 weeks initially – confirm stable + UPC response
• Every 3-6 months stable

Expected Changes

• BUN/Cr increase 10-25% acceptable (from preload reduction)
• Greater than 30% increase = reduce dose or discontinue
• K+ may rise – hyperkalemia if over 5.5; discontinue if over 6.5
• BP may drop modestly
• UPC should decrease – target 50% reduction over 4-8 weeks

Contraindications

• Severe dehydration – stabilize first
• Hypotension (SBP <90 mmHg)
• Severe hyperkalemia (K >6.0)
• Acute kidney injury
• Bilateral renal artery stenosis (rare)
• Pregnancy – teratogenic (fetal renal abnormalities)
• Hypersensitivity

Side Effects

Uncommon

• Decreased appetite
• GI upset
• Lethargy
• Hyperkalemia (especially with K+-sparing diuretics or NSAIDs)
• Mild azotemia

Rare

• Hypotension
• Cough – rare in dogs (unlike humans where common)
• Renal failure (especially with NSAID)
• Angioedema
• Skin reactions
• Hepatic dysfunction

Drug Interactions

AVOID

• NSAIDs (carprofen, meloxicam, etc.) – triple whammy
• K+ supplements – hyperkalemia
• K+-sparing diuretics (high-dose spironolactone)
• Pregnancy – teratogenic

Monitor Closely

• Furosemide – standard CHF combo
• Spironolactone 1-2 mg/kg standard
• Amlodipine – BP combination
• Telmisartan – refractory proteinuria

Questions This Calculator Answers

• “How much benazepril for my dog?” – 0.25-0.5 mg/kg PO once daily
• “What is benazepril for?” – CHF, CKD proteinuria, hypertension, PLN
• “Benazepril vs enalapril?” – Benazepril preferred in CKD (dual elimination)
• “Side effects?” – Uncommon; GI upset, hyperkalemia, mild azotemia; cough RARE in dogs
• “Benazepril + furosemide?” – Standard CHF combo
• “Benazepril + NSAID?” – AVOID – triple whammy AKI
• “How long until it works?” – Peak effect 2-4 weeks
• “Can be split?” – Yes – uncoated splittable
• “For proteinuria?” – 0.25-0.5 mg/kg; target 50% UPC reduction

Practical Tips

1. Once-daily dosing simplifies compliance
2. With or without food (no major effect)
3. Uncoated splittable tablets
4. Pill pockets, cheese, peanut butter for administration
5. NEVER combine with NSAIDs in dogs on diuretic
6. Maintain water access
7. Storage at room temperature
8. Generic + brand equivalent

Conclusion

Benazepril at 0.25-0.5 mg/kg PO once daily is the preferred ACE-inhibitor for dogs with CKD due to dual hepatic + renal elimination. Standard CHF quad therapy includes benazepril alongside furosemide + pimobendan + spironolactone. Triple-whammy NSAID + diuretic + ACE-i is the most important interaction to avoid. Monitor BUN/Cr/K+ at 5-7 days then 2-4 weeks. Pregnancy contraindicated. Cough rare in dogs (unlike humans). Target 50% UPC reduction in proteinuric CKD over 4-8 weeks.

Frequently Asked Questions

How much benazepril should I give my dog?

STANDARD DOSE: 0.25-0.5 mg/kg PO every 24 hours. HIGHER DOSE for protein-losing nephropathy: 0.5-1.0 mg/kg PO every 12-24 hours. EXAMPLES (standard 0.25-0.5 mg/kg q24h): 1) 5 kg (11 lb) dog: 1.25-2.5 mg once daily; 2) 10 kg (22 lb): 2.5-5 mg once daily; 3) 15 kg (33 lb): 3.75-7.5 mg once daily; 4) 20 kg (44 lb): 5-10 mg once daily; 5) 30 kg (66 lb): 7.5-15 mg once daily; 6) 40 kg (88 lb): 10-20 mg once daily. TABLETS: 2.5, 5, 10, 20, 40 mg – splittable (uncoated). BRAND NAMES: Fortekor (veterinary brand), Lotensin (human brand), generic widely available. INDICATION-SPECIFIC DOSING: 1) CHF (ACVIM Stage C+) – 0.25-0.5 mg/kg q24h; combined with furosemide + pimobendan + spironolactone; 2) CKD WITH PROTEINURIA (UPC over 0.5) – START 0.25 mg/kg q24h, titrate up to 0.5 mg/kg based on UPC response; 3) HYPERTENSION – 0.25-0.5 mg/kg q24h; often combined with amlodipine for moderate-severe; 4) PROTEIN-LOSING NEPHROPATHY – HIGHER dose 0.5-1.0 mg/kg q12-24h; consider telmisartan adjunct; 5) DCM CHF – 0.25-0.5 mg/kg q12-24h; 6) HGE/ENDOTOXIN – 0.25-0.5 mg/kg q24h support. STARTING STRATEGY: 1) START LOW end of range (0.25 mg/kg); 2) Baseline bloodwork (BUN, creatinine, K+) before starting; 3) Recheck 5-7 days after starting; 4) Titrate up based on response + tolerability; 5) Maximum 1.0 mg/kg in special cases; 6) Once-daily dosing standard but BID for severe CHF or PLN. ADMINISTRATION: 1) With or without food (no major effect); 2) UNCOATED tablets splittable; 3) Pill pockets, cheese, peanut butter (verify no xylitol); 4) Some dogs accept easily; 5) Compounded liquid available very small dogs; 6) Consistent timing helps. RENAL ADJUSTMENT: 1) Normal kidney function – standard dose; 2) IRIS 1-2 CKD – no adjustment needed (dual elimination); 3) IRIS 3 – usually no adjustment but monitor; 4) IRIS 4 – 75-85% dose, monitor closely; 5) Acute kidney injury – CONTRAINDICATED. WHY BENAZEPRIL VS ENALAPRIL: 1) BENAZEPRIL has DUAL hepatic + renal elimination; 2) ENALAPRIL primarily renal elimination; 3) BENAZEPRIL preferred in CKD; 4) Once-daily dosing benazepril simpler; 5) Active metabolite benazeprilat has 22-hour half-life. EXPECTED BLOODWORK CHANGES: 1) BUN/Cr increase 10-25% from preload reduction – ACCEPTABLE; 2) Greater than 30% increase = reduce dose; 3) K+ may rise modestly; 4) BP may drop; 5) UPC should decrease 50% target over 4-8 weeks. NEVER COMBINE with NSAIDs (carprofen, meloxicam, etc.) – TRIPLE WHAMMY with furosemide = AKI risk. Use gabapentin, Librela, Adequan for arthritis instead. WORK WITH VETERINARIAN for proper dosing, monitoring, drug interaction screening.

What is benazepril used for in dogs?

Benazepril is used in dogs for FOUR PRIMARY INDICATIONS: 1. CONGESTIVE HEART FAILURE (CHF) – ACVIM Stage C+ – dose 0.25-0.5 mg/kg q24h – standard quad therapy with furosemide, pimobendan, spironolactone; survival benefit demonstrated in BENCH + CONSENSUS clinical trials; particularly for myxomatous mitral valve disease (MVD) and dilated cardiomyopathy (DCM). Reduces afterload (vasodilation), decreases aldosterone (reduces fluid retention), neurohormonal blockade slows progression. 2. CHRONIC KIDNEY DISEASE WITH PROTEINURIA – UPC ratio over 0.5 – dose 0.25-0.5 mg/kg q24h – per IRIS (International Renal Interest Society) guidelines; reduces intraglomerular pressure by dilating efferent arteriole; decreases proteinuria; slows CKD progression; renal-protective. Particularly important for: a) Hereditary nephropathies (Soft-Coated Wheaten, Doberman, Bernese); b) Glomerulonephritis; c) Amyloidosis; d) Chronic interstitial nephritis with proteinuria. 3. SYSTEMIC HYPERTENSION – dose 0.25-0.5 mg/kg q24h – modest BP reduction (10-15 mmHg systolic typically); often inadequate as monotherapy; combine with AMLODIPINE 0.1-0.5 mg/kg q24h for moderate-severe (SBP over 180); target SBP under 160 mmHg in CKD/hypertension; CKD is most common hypertension cause in dogs. 4. PROTEIN-LOSING NEPHROPATHY (PLN) – HIGHER dose 0.5-1.0 mg/kg q12-24h – severe proteinuria from glomerular disease; reduces protein loss; may need telmisartan (ARB) combination for refractory cases; renal diet adjunct essential. ADDITIONAL/OFF-LABEL USES: 1) HEMORRHAGIC GASTROENTERITIS (HGE) with septic shock – RAAS support during fluid resuscitation; 2) ENDOTOXEMIA – cardiovascular support; 3) HEARTWORM TREATMENT adjunctive – RAAS blockade may reduce pulmonary pathology; 4) CARDIOMYOPATHIES non-MVD – DCM (Doberman, Boxer, Great Dane); 5) CHF FROM CONGENITAL DISEASE – mitral dysplasia, tricuspid dysplasia, PDA; 6) MITRAL VALVE PROLAPSE; 7) PERICARDIAL DISEASE adjunctive. PRECLINICAL B2 MVD – NOT RECOMMENDED: 1) SVEP trial showed neutral effect of ACE-inhibitor in preclinical MVD; 2) PIMOBENDAN preferred for B2 per EPIC trial – delays CHF onset ~15 months; 3) Don’t start benazepril until Stage C clinical CHF develops. EVIDENCE BASIS: 1) BENCH trial – benazepril improved survival in dogs with CHF from MVD or DCM; 2) CONSENSUS – similar findings; 3) IMPROVE – imidapril similar ACE-i; 4) Multiple studies in proteinuric CKD – reduces UPC, slows progression; 5) IRIS guidelines incorporate evidence base. MECHANISM RECAP: 1) Blocks ACE – prevents conversion angiotensin I to angiotensin II; 2) Reduces vasoconstriction – lowers BP, afterload reduction; 3) Reduces aldosterone – less Na+/water retention; 4) Dilates EFFERENT arteriole > AFFERENT in kidneys – decreases intraglomerular pressure – REDUCES PROTEINURIA + slows CKD; 5) Reduces ventricular remodeling in CHF; 6) Neurohormonal blockade. WHO BENEFITS MOST: 1) Dogs with proteinuric CKD (UPC over 0.5); 2) Dogs with hypertension and proteinuria; 3) Dogs with MVD CHF (Stage C+); 4) Dogs with DCM CHF; 5) Dogs with protein-losing nephropathy; 6) Dogs with hereditary nephropathies. WORK WITH VETERINARIAN to determine if benazepril appropriate, correct dose, monitoring plan, drug interaction screening, and integration with other CHF/CKD medications.

Benazepril vs enalapril for dogs – which is better?

BENAZEPRIL preferred in DOGS WITH CKD due to dual hepatic + renal elimination. EQUIVALENT efficacy in dogs without CKD – choice often based on availability, cost, owner preference. KEY DIFFERENCES: 1) ELIMINATION: BENAZEPRIL dual hepatic + renal (~50:50) – preferred when one route impaired; ENALAPRIL primarily renal – accumulates in CKD; 2) HALF-LIFE (active metabolite): BENAZEPRILAT ~22 hours – reliable once-daily dosing; ENALAPRILAT ~10-15 hours – may need BID for sustained effect; 3) DOSING FREQUENCY: BENAZEPRIL once daily; ENALAPRIL may need q12h for CHF; 4) DOSE: BOTH 0.25-0.5 mg/kg PO; 5) BIOAVAILABILITY: BENAZEPRIL ~37% absolute; ENALAPRIL ~60% absolute; 6) BRANDS: BENAZEPRIL = Fortekor (vet), Lotensin (human); ENALAPRIL = Enacard (vet), Vasotec (human); 7) COST: ENALAPRIL slightly cheaper typically; BENAZEPRIL competitive especially generic; 8) AVAILABILITY: Both widely available generic. WHEN TO CHOOSE BENAZEPRIL: 1) CKD especially moderate-severe (IRIS 3-4); 2) Need once-daily dosing for compliance; 3) Concurrent hepatic disease less concerning (benazepril activates in liver but eliminated dual route); 4) Standard veterinary CHF protocols use Fortekor in many countries; 5) Preference for proven preferred in CKD. WHEN ENALAPRIL APPROPRIATE: 1) Normal renal function; 2) CHF without significant CKD; 3) Cost-sensitive owner; 4) Generic availability; 5) Familiarity of prescribing veterinarian; 6) Historical use in BENCH/COVE trials. OTHER ACE-INHIBITORS USED IN DOGS: 1) IMIDAPRIL (Prilium) – similar to benazepril; used in some European markets; 2) RAMIPRIL (Vasotop, Cardace) – dual elimination similar to benazepril; once-daily; 3) CAPTOPRIL – short half-life; rarely used now; 4) LISINOPRIL – human ACE-i; not commonly used in dogs (less data). PRACTICAL CONSIDERATIONS: 1) Once started, generally continue same ACE-i; 2) Switch only for specific indication (CKD progression, response inadequacy, cost); 3) When switching, dose-equivalent transition; 4) Monitor for changes during transition; 5) Owner adherence higher with once-daily dosing. CONVERSION: 1) Direct switch generally OK; 2) 0.25-0.5 mg/kg of either drug; 3) Both prodrugs (require hepatic activation); 4) Both same mechanism of action; 5) Reassess in 1-2 weeks after switch. CKD-SPECIFIC DOSE ADJUSTMENTS: 1) BENAZEPRIL: IRIS 1-3 – standard dose; IRIS 4 – 75-85% dose; 2) ENALAPRIL: IRIS 1 standard; IRIS 2-3 – 75% dose, less frequent; IRIS 4 – 50% dose – or switch to benazepril; 3) Severe CKD – benazepril or ARB (telmisartan) preferred. WHICH ONE FOR PROTEIN-LOSING NEPHROPATHY: 1) BENAZEPRIL at HIGHER dose 0.5-1.0 mg/kg q12-24h – preferred; 2) Consider telmisartan ARB as adjunct/alternative; 3) Combination ACE-i + ARB possible refractory but increased risk; 4) Higher dose tolerated short-term but monitor closely. INTERACTIONS – same for both: 1) NSAIDs – TRIPLE WHAMMY with diuretic = AKI; 2) K+ supplements – hyperkalemia; 3) K+-sparing diuretics – K+ rise; 4) Lithium accumulation; 5) Pregnancy contraindicated. SIDE EFFECT PROFILE – same for both: 1) Decreased appetite uncommon; 2) GI upset uncommon; 3) Hyperkalemia (especially with NSAIDs/K+); 4) Mild azotemia (acceptable); 5) Hypotension uncommon; 6) Cough RARE in dogs (unlike humans). BOTTOM LINE: 1) BENAZEPRIL = preferred for CKD due to dual elimination + once-daily dosing; 2) ENALAPRIL = acceptable alternative without significant CKD; 3) BOTH effective for CHF, hypertension, proteinuria; 4) Choice often based on clinical situation, availability, cost, prescriber preference; 5) Continue established medication unless specific indication to change; 6) MONITOR carefully on either drug.

What are benazepril side effects in dogs?

GENERALLY WELL-TOLERATED – most dogs experience few side effects. LOW RATES overall. UNCOMMON (1-10%): 1) DECREASED APPETITE – mild; usually transient; may need dose adjustment; 2) GI UPSET – mild vomiting, diarrhea; give with food if persistent; 3) LETHARGY – mild; assess for dehydration or hypotension; 4) HYPERKALEMIA – K+ over 5.5 mmol/L; especially with K+ supplements, K+-sparing diuretics, NSAIDs, severe CKD; 5) MILD AZOTEMIA – 10-25% BUN/Cr increase expected from preload reduction – acceptable; greater than 30% = reduce dose; 6) HYPOTENSION – rare unless dehydrated or other vasodilators; 7) Skin reactions – mild rash, pruritus. RARE BUT SERIOUS: 1) ACUTE KIDNEY INJURY – especially with NSAID + diuretic (triple whammy); 2) SEVERE HYPERKALEMIA (K over 6.5) – cardiac arrhythmias possible; emergency; 3) ANGIOEDEMA – swelling of face, lips, airway; rare but life-threatening; emergency; 4) HEPATIC DYSFUNCTION – rare, monitor; 5) ANAPHYLAXIS – extremely rare; emergency; 6) NEUTROPENIA – rare; 7) PANCREATITIS – rare association. COUGH – very RARE in dogs (unlike humans): 1) In humans, ACE-inhibitors cause persistent dry cough in 10-20% (bradykinin-mediated); 2) In dogs, cough side effect uncommon; 3) If dog on ACE-i develops new cough, MORE LIKELY pulmonary edema (CHF worsening) than ACE-i side effect; 4) Always investigate cough cause; 5) Don’t attribute cough to ACE-i without ruling out CHF decompensation. PREGNANCY TERATOGENICITY: 1) ABSOLUTELY CONTRAINDICATED in pregnant dogs; 2) Fetal renal dysgenesis; 3) Oligohydramnios; 4) Fetal death; 5) Congenital abnormalities; 6) Avoid in breeding females; 7) Effective contraception if dog must remain on therapy. SIDE EFFECT MITIGATION: 1) START LOW dose; 2) BASELINE bloodwork before starting; 3) RECHECK 5-7 days; 4) MONITOR with each dose change; 5) AVOID NSAIDs concurrent; 6) AVOID K+ supplements; 7) ENSURE hydration; 8) WATCH for clinical signs; 9) PROMPT vet contact if concerning. EXPECTED CHANGES (acceptable, not side effects): 1) Mild BUN/Cr increase 10-25%; 2) Mild K+ increase; 3) Mild BP decrease; 4) Decreased proteinuria; 5) Reduced fluid retention; 6) Improved cardiac output indirectly. WHEN TO STOP/REDUCE BENAZEPRIL: 1) BUN/Cr increase over 30% baseline; 2) K+ over 5.5-6.0 mmol/L; 3) Symptomatic hypotension; 4) Severe dehydration develops; 5) AKI; 6) Severe GI signs; 7) Hypersensitivity; 8) Pregnancy confirmed; 9) Before contrast studies; 10) Before surgery if instructed. DRUG INTERACTIONS causing side effects: 1) NSAIDs + benazepril + diuretic = AKI (TRIPLE WHAMMY); 2) K+ supplements + benazepril = hyperkalemia; 3) K+-sparing diuretics + benazepril = hyperkalemia; 4) Other vasodilators + benazepril = hypotension; 5) Lithium + benazepril = lithium toxicity. SIDE EFFECTS BY PATIENT POPULATION: 1) ELDERLY dogs – more side effects; start lower; 2) CKD – hyperkalemia + azotemia more likely; 3) CHF dogs – dehydration risk; 4) Concurrent multiple medications – more interactions; 5) Smaller dogs – precise dosing critical. MONITORING PROTOCOL: 1) BASELINE – BUN, Cr, K, Na, Cl, USG, UPC, BP; 2) 5-7 days – BUN, Cr, K; 3) 2-4 weeks – BUN, Cr, K, UPC, BP; 4) 3-6 months stable – similar full panel; 5) After dose change – 1 week recheck; 6) During illness – more frequent. WHEN TO CONTACT VET: 1) Loss of appetite over 1-2 days; 2) Vomiting/diarrhea persistent; 3) Marked lethargy; 4) Weakness, collapse; 5) Difficulty breathing; 6) Decreased urination; 7) Face/airway swelling (angioedema); 8) Concerning bloodwork changes; 9) Other concerning symptoms. PROGNOSIS with appropriate management: 1) Most dogs tolerate well long-term; 2) Side effects usually reversible with dose adjustment; 3) Benefits typically outweigh risks; 4) Survival benefits documented; 5) Quality of life improvement common; 6) Routine monitoring keeps risks manageable. BENAZEPRIL IS GENERALLY WELL-TOLERATED in dogs with proper monitoring. Side effects most often related to interactions or pre-existing conditions rather than the drug itself. Communicate with veterinarian about any concerning signs.

Can I give my dog benazepril and NSAIDs together?

AVOID if possible – significant TRIPLE WHAMMY risk if also on diuretic. WHY DANGEROUS: 1) BENAZEPRIL (ACE-i) reduces glomerular filtration pressure (dilates efferent arteriole); 2) DIURETICS (furosemide) cause volume depletion; 3) NSAIDs inhibit prostaglandins that maintain renal blood flow during volume depletion; 4) ALL THREE TOGETHER = significantly increased acute kidney injury risk; 5) Documented in human + veterinary literature; 6) Real clinical problem – not theoretical. THE TRIPLE WHAMMY EFFECT: 1) Each medication alone – usually OK; 2) Two together – increased risk; 3) ALL THREE together – 30% AKI risk in human studies; 4) Veterinary risk less precisely quantified but similar pathophysiology; 5) Common scenario – older dog with CHF (on benazepril + furosemide) develops arthritis. RISK FACTORS for severe interaction: 1) Older age; 2) Pre-existing CKD; 3) Dehydration; 4) High diuretic doses; 5) Long-term concurrent use; 6) Hypovolemia from any cause; 7) Concurrent illness; 8) Recent surgery. NSAIDS to specifically AVOID: 1) CARPROFEN (Rimadyl, Novox, Vetprofen, Carprovet, Rovera); 2) MELOXICAM (Metacam, Loxicom, Meloxidyl); 3) FIROCOXIB (Previcox); 4) ROBENACOXIB (Onsior); 5) DERACOXIB (Deramaxx); 6) GRAPIPRANT (Galliprant) – safer profile but still NSAID class – use very cautiously; 7) ASPIRIN – additional cardiac concerns; 8) HUMAN NSAIDs (ibuprofen, naproxen) – NEVER give dogs anyway. SAFER ALTERNATIVES for arthritis in CHF/CKD dog: 1) GABAPENTIN 10-20 mg/kg PO q8-12h – no renal/GI effects; pain control; 2) LIBRELA (bedinvetmab) – monoclonal antibody anti-NGF; monthly subcutaneous injection; SAFE for cardiac/renal patients; excellent option; 3) ADEQUAN (PSGAG) – polysulfated glycosaminoglycan injections; weekly then monthly; joint health; 4) OMEGA-3 (fish oil EPA/DHA) – anti-inflammatory; cardioprotective + renal-friendly; 5) GLUCOSAMINE/CHONDROITIN supplements (Dasuquin, Cosequin) – joint support; 6) GREEN-LIPPED MUSSEL – anti-inflammatory omega-3 source; 7) ACUPUNCTURE – good for chronic pain; 8) LASER THERAPY (Class IV) – pain reduction; 9) PHYSICAL THERAPY/HYDROTHERAPY – mobility + strength; 10) WEIGHT MANAGEMENT – reduce joint stress; 11) AMANTADINE 3-5 mg/kg q24h – chronic pain modulation; 12) MAROPITANT (Cerenia) 2 mg/kg q24h – mild anti-inflammatory; 13) CYTOPOINT for pruritus (not pain); 14) TRAMADOL – limited efficacy but safer than NSAID; 15) THERAPEUTIC DIETS (Hill’s j/d, Royal Canin Mobility) – integrated joint support. IF NSAID ABSOLUTELY NECESSARY (after exhausting alternatives): 1) Veterinary risk-benefit discussion; 2) Cardiology + nephrology consultation if possible; 3) LOWEST effective dose; 4) SHORTEST possible duration; 5) MONITOR bloodwork weekly initially: BUN, Cr, K+, Na, Cl, USG, ALT; 6) MONITOR blood pressure; 7) ENSURE adequate hydration; 8) AVOID dehydration; 9) WATCH for AKI signs: vomiting, anorexia, lethargy, decreased urine; 10) ELECTROLYTE monitoring; 11) Consider PPI (omeprazole) for GI protection; 12) STOP at first sign of trouble; 13) Discuss prognosis. AKI WARNING SIGNS: 1) DECREASED appetite; 2) VOMITING; 3) LETHARGY; 4) Decreased urine output; 5) Increased BUN/Cr on bloodwork; 6) Decreased urine specific gravity; 7) Tremors, weakness; 8) Collapse. ACTION: STOP NSAID immediately + emergency vet visit. SEPARATION TIMING: 1) Benazepril half-life ~22 hours (active metabolite); 2) NSAID half-lives vary 4-30 hours; 3) Cannot simply separate doses by hours – both linger; 4) Effective separation would require 24-48+ hours; 5) Better to use non-NSAID alternative. WHEN A DOG OFF BENAZEPRIL CAN HAVE NSAID: 1) Discontinue benazepril for 48 hours; 2) Verify hydration; 3) Verify renal function; 4) Then start NSAID; 5) Often not practical for CHF dog needing continuous benazepril. RECOMMENDED APPROACH: 1) NEVER combine in CHF/CKD dog; 2) Use non-NSAID multimodal pain management; 3) Communicate with vet about all medications; 4) Pharmacy double-check; 5) Owner education essential. BOTTOM LINE: AVOID NSAIDs in dogs on benazepril, especially if also on diuretic. Multiple safer alternatives exist for arthritis and pain control. Work with veterinarian for balanced cardiac + orthopedic management.

Does benazepril cause cough in dogs like in humans?

RARE in dogs – unlike humans where ACE-inhibitor cough occurs in 10-20%. If cough develops on benazepril, INVESTIGATE other causes first (CHF worsening more likely). WHY HUMANS GET ACE-i COUGH: 1) ACE-inhibitors block ACE which also degrades BRADYKININ + SUBSTANCE P; 2) ACCUMULATION of bradykinin in respiratory tract; 3) Causes persistent DRY cough; 4) Bothersome but not dangerous; 5) Resolves with discontinuation; 6) Common reason for switching to ARB (which doesn’t affect bradykinin). WHY DOGS GET LESS COUGH: 1) Different bradykinin receptor distribution; 2) Less bradykinin-mediated cough response; 3) Species variation in ACE-i pharmacology; 4) RARELY reported in veterinary literature; 5) Some cases reported but not frequent. IF DOG ON BENAZEPRIL DEVELOPS COUGH: 1) DO NOT assume it’s medication side effect; 2) INVESTIGATE other causes: a) CHF DECOMPENSATION – most common cause; pulmonary edema returning; check sleeping respiratory rate; b) CHRONIC BRONCHITIS – common comorbidity; c) TRACHEAL COLLAPSE – small breeds; d) LARYNGEAL PARALYSIS – older large breeds; e) PNEUMONIA; f) HEARTWORM disease; g) NEOPLASIA; h) FOREIGN BODY; i) Chronic bronchitis; j) Bordetella/kennel cough; k) Allergic component. 3) VET ASSESSMENT: a) Chest X-rays – rule out pulmonary edema, mass, pneumonia; b) Echocardiogram if CHF progression suspected; c) Heartworm test; d) CBC + chemistry; e) Possibly bronchoalveolar lavage if chronic; 4) ADJUST CHF MEDICATIONS if decompensation – usually increase diuretic; 5) TREAT underlying cause – antibiotics for pneumonia, bronchodilators for collapse, etc. WHEN BENAZEPRIL COUGH SUSPECTED: 1) After excluding other causes; 2) Cough started shortly after starting benazepril; 3) DRY (non-productive) cough; 4) No CHF signs; 5) Otherwise stable. MANAGEMENT IF ACE-i COUGH CONFIRMED: 1) Discontinue benazepril; 2) Switch to ARB (TELMISARTAN, LOSARTAN) – similar effects but no bradykinin accumulation; 3) Equivalent RAAS blockade; 4) No cough side effect; 5) Continue monitoring CHF; 6) Telmisartan 0.5-1 mg/kg PO q24h. ARB ALTERNATIVES: 1) TELMISARTAN (Semintra in cats, available human) – 0.5-1 mg/kg q24h; 2) LOSARTAN – less common in vet medicine; 3) IRBESARTAN; 4) VALSARTAN; 5) Olmesartan; 6) Sacubitril-valsartan combination – investigational dogs. COUGH IN HUMAN ACE-i PATIENTS: 1) 10-20% incidence; 2) DRY, hacking, persistent; 3) Worse at night; 4) Disappears in 1-4 weeks after stopping; 5) Recurs if rechallenged; 6) Bradykinin-mediated; 7) Reason for many human switches to ARB. DIFFERENTIAL DIAGNOSIS for cough in dog on benazepril: 1) CHF PULMONARY EDEMA (most common) – check sleeping RR; 2) CHRONIC BRONCHITIS – older small breeds; 3) TRACHEAL COLLAPSE – toy breeds; 4) NEOPLASIA – older dogs; 5) PNEUMONIA – acute infection; 6) PARASITES (heartworm, lungworm); 7) ALLERGIC airway disease; 8) Foreign body; 9) Reflux cough; 10) ACE-i side effect (rare). ADDITIONAL CONSIDERATIONS: 1) BENEFITS of benazepril usually outweigh cough side effect even if present; 2) Switching to ARB if bothersome; 3) Cough doesn’t mean benazepril must be stopped – assess severity and impact; 4) Most coughs in CHF dogs are NOT from benazepril; 5) PROPER WORKUP essential rather than assumption. SO TO SUMMARIZE: 1) Cough on benazepril rare in dogs; 2) Investigate other causes (especially CHF) first; 3) If confirmed ACE-i cough, switch to ARB; 4) Don’t discontinue without alternative; 5) Communicate with vet about new cough.

Related PuppaDogs Calculators

Continue building your dog’s personalised care plan with these related PuppaDogs calculators:

• Dog Pregnancy / Whelping Due-Date Calculator
• Puppy Weight Predictor (Adult Weight Calculator)
• Heatstroke Risk Calculator for Dogs
• Bloat (GDV) Risk Calculator for Dogs
• Dog Life Expectancy Calculator (Breed, Body Condition, Lifestyle)
• Spay/Neuter Timing Calculator for Dogs (Breed-Specific)

Related Articles & Guides

Read the in-depth PuppaDogs guides that explain the science and clinical context behind this calculator:

• Benazepril for Dogs: Benefits, Dosage, Side Effects, and More

References & Further Reading

The dosing ranges and safety information on this page are drawn from the following veterinary references. Always defer to your own veterinarian and the manufacturer’s label for your specific product.

1. Plumb DC. Plumb’s Veterinary Drug Handbook – benazepril.
2. Keene BW et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. JVIM 2019.
3. BENCH Study Group. Effects of benazepril on survival of dogs with CHF. JVIM 1999.
4. Brown S et al. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. JVIM 2007.
5. IRIS Consensus on diagnosis and management of CKD in dogs and cats.
6. Polzin DJ. Chronic kidney disease in small animal medicine.
7. Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine.
8. Fortekor (benazepril) product information – Elanco/Novartis.
9. Atkins C, Bonagura JD. Cardiopulmonary medicine.
10. Lefebvre HP et al. Angiotensin-converting enzyme inhibitors in veterinary medicine.
11. King JN et al. The effect of benazepril in dogs with myocardial dysfunction.
12. PuppaDogs. Mitral Valve Disease ACVIM Stage Calculator, IRIS Kidney Disease Staging Calculator, Furosemide Dosage Calculator, Telmisartan Dosage Calculator. puppadogs.com.

Suyash Dhoot